Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant adjunctive therapy for seizures associated with tuberous sclerosis complex
2021-000838-34Phase 2Active
- Sponsor
- Noema Pharma
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of basimglurant in tuberous sclerosis complex (TSC) (3 arms), sponsored by Noema Pharma. Primary endpoint: Estimand 1a. Started Jan 2023; status: active.
02
Drugs
basimglurant
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2021-000838-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000838-34.